Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: A prospective and descriptive study of 19 patients

Menezes, Nuno; Lima, Ricardo; Moreira, Ana Sofia Linhares; Varela, Paulo; Barroso, Ana; Baptista, Armando; Parente, Bárbara

doi:10.1684/ejd.2009.0650

Cited by 13 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, complete responses were achieved in 3 of 5 cases with both the facial and the upper trunk involvement, but 4 of 5 patients in whom the face was the only involved location achieved only partial responses. 17 Hu et al recommend topical retinoid as a possible treatment in grade 1 and grade 2 acneiform eruptions, 6 whereas Scope et al found that topical tazarotene treatment was associated with significant irritation, leading to discontinuation in one-third of patients; therefore, it is not recommended for cetuximab-related rash. 18 Monoclonal antibodies such as cetuximab can cause infusionassociated reactions.…”

Section: Anaphylactic Infusion Reactionmentioning

confidence: 99%

Cetuximab‐induced cutaneous toxicity

Tomková¹,

Kohoutek²,

Zábojníková³

et al. 2010

Acad Dermatol Venereol

View full text Add to dashboard Cite

The most frequent cutaneous side effect reported in this series was acneiform eruption. The authors observed that all women with acneiform rash had only limited facial involvement, whereas all but one man experienced more widespread lesions of the face, the back and the chest. We found no association between the extent and severity of cutaneous eruptions (grade 1 vs. grade 2) and patients' response to therapy.

show abstract

Section: Anaphylactic Infusion Reactionmentioning

confidence: 99%

Cetuximab‐induced cutaneous toxicity

Tomková¹,

Kohoutek²,

Zábojníková³

et al. 2010

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…All 3 RCTs 31-33 and 5 of the 7 studies with other prospective designs supported their use. [34][35][36][37][38] Topical corticosteroids were recommended as a rash management intervention in 24 of the 59 articles identifed in this review, however, relatively little clinical evidence was identifed to supports this recommendation. Topical and oral retinoids are also recommended for rash management (Table 2), although they are less often recommended than antibiotics or corticosteroids.…”

Section: Rash Management Interventionsmentioning

confidence: 99%

Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review

Brown¹,

Su²,

Nelleson³

et al. 2016

J Community Support Oncol

View full text Add to dashboard Cite

Cancer patients treated with epidermal growth factor receptor inhibitors (EGFRIs) frequently experience skin toxicities (rash) that can compromise their quality of life and lead to dose reduction or discontinuation of treatment. Reflecting the need for effective management of EGFRI-associated rash, a number of clinical practice guidelines and management recommendations have been developed. The objective of this systematic review is to identify and summarize all available published recommendations of rash management strategies and evaluate their basis of evidence, to describe consensus in the recommendations, and where there is a lack of consensus to describe the opportunities for future clinical research to improve clinical practice in the management of EGFRI rash. Fifty-nine articles published from 2005-2011 were selected for inclusion in the systematic review. Common drug recommendations were oral and topical antibiotics, topical corticosteroids, and antihistamines; low-grade rash was generally recommended to be managed with topical antibiotics or corticosteroids, grade 2 rash with oral antibiotics or antihistamines, and severe grades of rash with oral corticosteroids or delay/dose reduction of EGFRI. The focus of clinical practice guidelines and recommendations was on reactive management. A better understanding of pre-emptive versus reactive treatment with the implementation of appropriately designed randomized controlled studies could support a more effective management of EGFRI-associated rash and improve patient outcomes. Consideration of patients' self-reported outcomes and consistent grading of rash toxicity are also recommended. Funding/sponsor: Eli Lilly & Co, Bristol-Myers Squibb.

show abstract

“…No randomised study investigated the efficacy of cyclines as curative treatment for folliculitis; seven publications of one to four clinical cases and three nonrandomised, prospective series of 11 to 24 patients reported the results of curative treatment with minocycline, doxycycline or tetracycline in conjunction with different local topical agents to varying degrees [22][23][24][25]. Cycline treatment with or without topical treatment was reported to be effective and associated with a reduction in the grade of folliculitis.…”

Section: Folliculitismentioning

confidence: 99%